Outcome of patients after treatment for a squamous cell carcinoma of the oropharynx

Laryngoscope

Volumn 119, Issue 3, 2009, Pages 534-540

  Röösli, Christof ^a,b   Tschudi, Dominique C ^a   Studer, Gabriela ^b   Braun, Julia ^c   Stoeckli, Sandro J ^a,d  

^a Kantonsspital St Gallen   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Carcinoma; Oropharynx; Radiotherapy; Surgery; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; NECK DISSECTION; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; CANCER STAGING; COMPARATIVE STUDY; FOLLOW UP; METHODOLOGY; MIDDLE AGED; MORTALITY; OROPHARYNX TUMOR; PATHOLOGY; SURVIVAL RATE; SWITZERLAND;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SURVIVAL RATE; SWITZERLAND; TREATMENT OUTCOME;

EID: 64849093337     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20033     Document Type: Article

References (30)

1. Hoffman HT, Karnell LH, Funk GF, Robinson RA, Menck HR. The National Cancer Data Base report on cancer of the head and neck. Arch Otolaryngol Head Neck Surg 1998; 124:951-962.
2. Swiss Association of Cancer Registries. August 24, 2006. Available at: http://www.asrt.ch/asrt/newstat/extracted-from-globocan2002.pdf.
3. D'Souza G., Kreimer AR, Viscidi R., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356:1944-1956.
4. Hammarstedt L., Lindquist D., Dahlstrand H., et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 2006; 119: 2620-2623.
5. Perrone F., Mariani L., Pastore E., et al. p53 codon 72 polymorphisms in human papillomavirus-negative and human papillomavirus-positive squamous cell carcinomas of the oropharynx. Cancer 2007; 109:2461-2465.
6. Hicks WL Jr, Kuriakose MA, Loree TR, et al. Surgery versus radiation therapy as single-modality treatment of tonsillar fossa carcinoma: the Roswell Park Cancer Institute experience (1971-1991). Laryngoscope 1998; 108: 1014-1019.
7. Perez CA, Patel MM, Chao KS, et al. Carcinoma of the tonsillar fossa: prognostic factors and long-term therapy outcome. Int J Radiat Oncol Biol Phys 1998; 42:1077-1084.
8. Johansen LV, Grau C., Overgaard J. Squamous cell carcinoma of the oropharynx-an analysis of treatment results in 289 consecutive patients. Acta Oncol 2000; 39:985-994.
9. Lanza L., Rizzi L., Durso D., Occhini A., Benazzo M., Tinelli C. Integrated treatment in locally advanced carcinoma of the oropharynx. J Surg Oncol 2000; 74:75-78.
10. Zelefsky MJ, Harrison LB, Fass DE, Armstrong JG, Shah JP, Strong EW. Postoperative radiation therapy for squamous cell carcinomas of the oral cavity and oropharynx: impact of therapy on patients with positive surgical margins. Int J Radiat Oncol Biol Phys 1993; 25:17-21.
11. Pignon JP, Bourhis J., Domenge C., Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355:949-955.
12. Daly ME, Lieskovsky Y., Pawlicki T., et al. Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma. Head Neck 2007; 29:211-220.
13. Saarilahti K., Kouri M., Collan J., Hämäläinen T., Atula T., Joensuu H., Tenhunen M. http://www.ncbi.nlm.nih.gov/sites/entrez?Db= pubmed&Cmd=Search&Term=%22 Atula%20T%22%5BAuthor%5D&itool= EntrezSystem2.PEntrez.Pubmed.Pubmed-ResultsPanel.Pubmed-DiscoveryPanel. Pubmed-RVAbstractPlus http://www.ncbi.nlm.nih.gov/sites/entrez?Db= pubmed&Cmd=Search&Term=%22Joensuu%20H%22%5BAuthor%5D&itool= EntrezSystem2.PEntrez. Pubmed. Pubmed-ResultsPanel. Pubmed-Discovery Panel. Pubmed-RVAbstractPlus Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Radiother Oncol 2005; 74:251-258.
14. Tschudi D., Stoeckli S., Schmid S. Quality of life after different treatment modalities for carcinoma of the oropharynx. Laryngoscope 2003; 113:1949-1954.
15. Wittekind C., Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. Cancer 2002; 94: 2511-2516.
16. Rothschild S., Studer G., Seifert B., et al. PET/CT staging followed by intensity-modulated radiotherapy (IMRT) improves treatment outcome of locally advanced pharyngeal carcinoma: a matched-pair comparison. Radiat Oncol 2007; 2:22.
17. Huguenin P., Beer KT, Allal A., et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004; 22:4665-4673.
18. Makitie AA, Pukkila M., Laranne J., et al. Oropharyngeal carcinoma and its treatment in Finland between 1995-1999: a nationwide study. Eur Arch Otorhinolaryngol 2006; 263:139-143.
19. Licitra L., Bernier J., Grandi C., Merlano M., Bruzzi P., Lefebvre JL. Cancer of the oropharynx. Crit Rev Oncol Hematol 2002; 41:107-122.
20. Kovacs AF, Mose S., Bottcher HD, Bitter K. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer. Strahlenter Onkol 2005; 181:26-34.
21. Al-Sarraf M., Pajak TF, Byhardt RW, Beitler JJ, Salter MM, Cooper JS. Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, respectable head and neck cancers. Int J Radiat Oncol Biol Phys 1997; 37:777-782.
22. Velich N., Vaszilko M., Nemeth Z., Szigeti K., Bogdan S., Barabas J., Szabo G. http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd= Search&Term=%22Barab%C3%A1s%20J%22%5BAuthor%5D&itool=EntrezSystem2. PEntrez.Pubmed.Pubmed-ResultsPanel.Pubmed-DiscoveryPanel.Pubmed-RVAbstractPlus Overall survival of oropharyngeal cancer patients treated with different treatment modalities. J Craniofac Surg 2007; 18:133-136.
23. Mantz CA, Vokes EE, Stenson K., et al. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer. Cancer J 2001; 7:140-148.
24. Jakobsen J., Hansen O., Jorgensen KE, Bastholt L. Lymph node metastases form laryngeal and pharyngeal carcinomas-calculation of burden of metastasis and its impact on prognosis. Acta Oncol 1998; 37:489-493.
25. Fein DA, Lee WR, Amos WR, et al. Oropharyngeal carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 1996; 34:289-296.
26. Buck G., Huguenin P., Stoeckli SJ. Efficacy of neck treatment in patients with head and neck squamous cell carcinoma. Head Neck 2008; 30:50-57.
27. Grecula JC, Smith RE, Rhoades CA, et al. Induction paclitaxel in previously untreated, resectable, advanced squamous cell carcinomas of head and neck. Cancer 2000; 89:2587-2596.
28. Eckardt A., Rades D., Rudat V., et al. [Prospective phase II study of neoadjuvant radiochemotherapy in advanced operable carcinoma of the mouth cavity. 3-year outcome]. Mund Kiefer Gesichtschir 2002; 6:117-121.
29. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937-1944.
30. Parson JT, Mendenhall WM, Stringer SP, et al. Squamous cell carcinoma of the oropharynx. Cancer 2002; 94: 2967-2980.